A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy
Phase of Trial: Phase IV
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms MAXIMA
- Sponsors Roche
- 10 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Dec 2011 Actual patient number changed from 540 to 541 as reported by ClinicalTrials.gov.
- 05 Dec 2011 Planned end date changed from 1 Sep 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.